US Vs. EU: Is Cell And Gene Therapy Reimbursement Easier Stateside?
Some Gene Therapy Manufacturers Have Opted Out Of Europe
A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.
